Amol Akhade: What after Immunotherapy?
Amol Akhade, Senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals, shared a post on LinkedIn:
“What after Immunotherapy?
This question is becoming more and more difficult and complicated.
Anti-TIGIT and Anti-LAG3 antibodies (vibostolimab and Favezelimab) are both discontinued by Merck due to negative results.
Maybe all the focus is now on Bispecifics?”
More posts featuring Amol Akhade.
Dr. Amol Akhade is a senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital.
He specialises in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplant.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023